甘李藥業(603087.SH):6個產品及相關品規擬中選胰島素專項集採
格隆匯11月28日丨甘李藥業(603087.SH)公吿,2021年11月26日,甘李藥業股份有限公司(簡稱“公司”、“甘李藥業”)參加了國家組織藥品集中採購和使用聯合採購辦公室(簡稱“聯合採購辦公室”)組織開展的第六批國家組織藥品集中帶量採購(胰島素專項)(簡稱“胰島素專項集採”)的投標工作。
根據聯合採購辦公室發佈的全國藥品集中採購擬中選結果公示文件,公司參與產品精蛋白人胰島素混合注射液(30R)、賴脯胰島素注射液、門冬胰島素注射液、甘精胰島素注射液、精蛋白鋅重組賴脯胰島素混合注射液(25R)及門冬胰島素30注射液均擬中選本次集中採購,所有參加組別均有品種擬中選A類。
根據本次胰島素專項集採規則,在本採購週期中,醫療機構將優先使用中選藥品,並確保完成約定採購量。同採購組內,中選產品按排名分為A、B、C三類。A類品種在獲得自身基礎量的同時還獲得具備分得C類中選產品的調出量資格,具體調出量分配將根據醫療機構最終實際使用情況確定。此外,公司仍可以由於醫療機構的選擇獲得集採約定採購量外的其他用量。
為了積極響應國家政策,降低醫保費用支出,減輕患者用藥負擔,本次集中採購公司擬中選價格與原銷售價格相比有一定程度下降,但公司所有組別均有品種中選A類,在獲得基礎量外還可獲得C類調出的分配量,有利於市場份額進一步提升。同時有利於患者治療方案升級,進一步加快胰島素用藥的更新換代,激發提高藥品可及性,加速國產替代,促進胰島素用藥市場進一步擴大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.